Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03422094 · ClinicalTrials.gov registry record · Phase 1
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03422094 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 3 participants.
The verdict
NCT03422094, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a single institution, open-label, multi-arm, pilot study assessing the safety, feasibility, and immunogenicity of a personalized neoantigen-based vaccine plus poly-ICLC (NeoVax) combined with immune checkpoint inhibitors in subjects with newly diagnosed, unmethylated glioblastoma.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- PROCEDURE Research blood draw
- BIOLOGICAL NeoVax
- PROCEDURE Leukapheresis for research
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03422094
The ClinicalTrials.gov registry entry for NCT03422094 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nivolumab is the first listed.
NCT03422094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03422094 about?
NCT03422094 is a clinical study titled "Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma". This is a single institution, open-label, multi-arm, pilot study assessing the safety, feasibility, and immunogenicity of a personalized neoantigen-based vaccine plus poly-ICLC (NeoVax) combined with immune checkpoint inhibitors in subjects with newly diagnosed, unmethylated glioblastoma.
What is the current status of trial NCT03422094?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2018-10-31. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03422094?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Research blood draw (PROCEDURE), NeoVax (BIOLOGICAL), Leukapheresis for research (PROCEDURE).
Who is sponsoring clinical trial NCT03422094?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.